a year ago

Pfizer Leads £40.5 Million Series A for Curve Therapeutics

  • Curve Therapeutics, a Southampton-based drug discovery startup, has raised £40.5 million in a Series A round led by Pfizer's investment arm

  • The company's Microcycle platform examines the survival mechanisms of solid tumours and targets vulnerabilities in multiple cancers

  • The investment will support the startup's development of its assets and expand the discovery platform beyond challenging and complex intracellular protein targets.

      • ProblemHealthcare

      "Many promising drug targets within cancer cells are difficult to target using conventional drug discovery methods, limiting the development of effective treatments."

      Solution

      "Curve Therapeutics has developed the Microcycle platform, a novel drug discovery platform that identifies and targets vulnerabilities in the survival mechanisms of solid tumours, enabling the development of new therapies for difficult-to-treat cancers."

      Covered on